Vitality Watch

Dossier pubmed preclinical 07-may-2026
Animal model, organoid, or cell-culture result — not yet human

FMO1 disrupts mitochondrial functional homeostasis through ROS-mediated mechanisms to drive chondrocyte senescence and hypertrophy.

Key claim: FMO1 elevates ROS and shifts mitochondria toward fission, driving p16/p21-mediated chondrocyte senescence and hypertrophy, while FMO1 inhibition or senolytic clearance (ABT-263) blunts these pathological phenotypes.

Abstract

OBJECTIVE: The induced membrane technique is a clinical strategy for managing large bone defects, which relies on endochondral ossification. However, the metabolic mechanisms regulating this process remain largely uncharacterized. We utilized scRNA-seq to analyze chondro-osseous dynamics during membrane-induced osteogenesis, with a specific focus on the role of FMO1. METHODS: Following the scRNA-seq profiling of human induced membranes, FMO1 function was examined using in vivo and in vitro models of triiodothyronine (T3)-induced chondrocyte hypertrophy. Mechanistic investigations incorporated FMO1 genetic knockdown and overexpression, pharmacological inhibition (methimazole), targeted mitochondrial functional assays, and senolytic clearance (ABT-263). RESULTS: FMO1, an enzyme typically associated with xenobiotic metabolism, was upregulated during chondrocyte hypertrophy. Both T3 stimulation and direct FMO1 overexpression increased intracellular and mitochondrial reactive oxygen species. This localized oxidative stress altered mitochondrial homeostasis by shifting organelle dynamics toward fission, characterized by Drp1 upregulation and Mfn1/2 downregulation. This structural imbalance induced cellular senescence via the p16/p21 axis, resulting in abnormal matrix mineralization and increased expression of catabolic markers (COL10A1, MMP13). Genetic knockdown or pharmacological inhibition of FMO1, as well as the clearance of senescent cells, reduced these hypertrophic and senescent phenotypes. CONCLUSIONS: We describe an FMO1-ROS-mitochondria axis that links metabolic oxidative stress to chondrocyte senescence. While baseline FMO1 expression occurs during physiological bone repair, its sustained activation drives pathological calcification and cartilage degeneration. Targeting this axis presents a potential biological strategy for modulating the osteogenic microenvironment and managing cartilage disorders.

Why this matters

Chondrocyte senescence and hypertrophy are proposed drivers of osteoarthritis, and identifying FMO1 as an upstream enzymatic node that tips mitochondrial dynamics toward fission-linked ROS gives the senescence-in-cartilage narrative a concrete druggable handle beyond generic antioxidants. The finding also reinforces the ABT-263 senolytic rescue paradigm in a joint-tissue model, adding to a growing preclinical roster where clearing p16/p21+ cells blunts tissue-specific aging phenotypes — while remaining a mouse/cell-level mechanistic result with no human translation.

Source

Link

Briefing card

FMO1 disrupts mitochondrial functional homeostasis through ROS-mediated mechanisms to drive chondrocyte senescence and hypertrophy.
Stage: preclinical · pubmed · 07-may-2026

Applies to preclinical osteoarthritis and chondrocyte-aging research; there is no human evidence that FMO1 inhibition or ABT-263 protects human joints.

FMO1 elevates ROS and shifts mitochondria toward fission, driving p16/p21-mediated chondrocyte senescence and hypertrophy, while FMO1 inhibition or senolytic clearance (ABT-263) blunts these pathological phenotypes.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.freeradbiomed.2026.04.158

build build 880 · 2bcef25 · 2026-11-18